# MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

> **NCT00094653** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1783 (actual)

## Conditions studied

- Melanoma
- Metastases

## Interventions

- **DRUG:** MDX-010 (anti-CTLA4) monoclonal antibody
- **BIOLOGICAL:** MDX-1379 (gp100) Melanoma Peptide Vaccine

## Key facts

- **NCT ID:** NCT00094653
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2009-08
- **Final completion:** 2009-10
- **Target enrollment:** 1783 (ACTUAL)
- **Last updated:** 2011-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094653, "MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00094653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*